Liquivida advertises an NAD+ IV drip through its clinic service menu. Its national NAD+ page describes an infusion visit lasting roughly two to four hours. For someone searching nearby, that makes appointment time, medical supervision, and a location-specific quote central to the comparison.
We checked the public service page on September 19, 2026. We did not book an infusion or verify availability at every location. This review focuses on the service the page describes and the practical and clinical questions that remain before a reader commits to a visit or package.
Liquivida is a clinic-infusion comparison. Obtain the local quote and screening process, and do not treat its broad wellness claims as established outcomes.
Build the appointment around the full time required
The Liquivida NAD+ page describes a slow infusion rather than a quick home injection. Ask how much additional time is needed for the first consultation, preparation, and any observation afterward. The national estimate is not a guarantee for your appointment.
If you work, care for someone else, or travel a long distance, include that time in the decision. Our IV-versus-injection guide explains why the two services have different practical demands. A longer visit should not be interpreted as proof of a stronger or more durable clinical benefit.
Ask the location for an itemized price
The national service page did not establish a single all-in price for every clinic. Request a quote for the chosen location and preparation, including any consultation, membership, package, or additional infusion charges. Ask whether the quoted rate applies to a first visit, a single session, or a prepaid course.
For a package, find out how unused visits are handled if treatment is not appropriate or is stopped. The cost guide helps separate the cost of staffing and an appointment from the cost of medication. A clinic invoice should not be compared directly with the price of a home vial alone.
The benefit claims need product-specific evidence
Liquivida’s page discusses energy, cognition, aging, and recovery, including strong language about health improvement. Those are provider claims. They do not demonstrate that this particular infusion reliably treats a diagnosed condition or produces the outcomes a visitor may infer from the marketing language.
Read the NAD+ evidence review and ask the clinician which human research supports the proposed use. For concerns such as substance-use recovery or persistent cognitive symptoms, an infusion advertisement should not replace condition-specific medical care. The consultation should leave room to discuss uncertainty, alternatives, and reasons not to proceed.
Know who is supervising and who follows up
Ask who performs medical screening, who administers the infusion, and how a concern during the visit is escalated. Also identify the clinician available after you leave. A relaxed setting may help comfort, but it is not the same as a clear plan for monitoring and responding to problems.
Request the pharmacy source and ask whether you can review the preparation’s label. Our pharmacy-checking guide applies even when you never handle the vial yourself. Knowing where the medication comes from and who is responsible for care makes a local service easier to evaluate.
Where Liquivida fits in a local shortlist
Compare Liquivida with Next Health, Prime IV, and Hydration Room when looking for a supervised infusion. Each has different public descriptions and pricing structures. A brand’s presence in this directory does not confirm a specific nearby branch or same-day appointment.
The near-me versus online guide can help if you are also considering a shipped prescription. Our CoreAge Rx review covers the commercial partner featured on this site. Liquivida’s role in the comparison is a local clinic experience with a substantial time commitment, not an interchangeable mail-order offer.
Follow the source
References & further reading
- Liquivida — NAD+ IV service
Checked September 19, 2026. Provider appointment estimate and service claims, not a confirmed local booking or all-in quote.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.